About EnanDIM®

EnanDIM® (Enantiomeric, DNA-based, ImmunoModulator) is an innovative linear DNA-based TLR-9 agonist in pre-clinical development. It broadly and strongly activates the immune system. EnanDIM® represents a new generation of immunoactivating TLR9 agonists and is therefore a follow-up compound to MOLOGEN TLR9 technology with longer patent protection.

EnanDIM® could be used in various cancer indications either as monotherapy, in combination with other targeted therapies or immune modulators, such as so called checkpoint inhibitors, or with other immunotherapeutic approaches. It could also potentially be used in the field of infectious diseases - such as HIV.